Replies to post #979 on Bristol Myers Squibb (BMY)

[DewDiligence]

Opdivo/Yervoy and Opdivo/chemo–>statsig-superior_OS_vs_chemo_alone_in_esophageal_cancer:

https://finance.yahoo.com/news/bristol-myers-squibb-announces-opdivo-105900131.html

No hazard ratios in the above PR. Detailed data from the CHECKMATE-648 study will be presented at an unspecified medical conference.

[DewDiligence]

FDA approves Opdivo monotherapy in adjuvant esophageal cancer (for patients who have residual pathological disease following chemo/radiation in the neoadjuvant setting and a complete resection):

https://finance.yahoo.com/news/u-food-drug-administration-approves-172600155.html

The approval was based on the CHECKMATE-577 study. Today was the PDUFA date.

This is Opdivo’s second approval in an adjuvant setting—the other is in melanoma.